Máster Virtual en Ingeniería Biomédica con Cooperación al Desarrollo

En el presente trabajo presentamos nuestra experiencia en desarrollar un programa de máster oficial en Ingeniería Biomédica. Para ello nos planteamos un lugar en común con las ingenierías en el cual las necesidades en salud pudieran ser percibidas por los ingenieros a fin de desarrollar soluciones. Para conseguir el nivel adecuado, consideramos fundamental que la docencia de los conocimientos sea realizada por expertos de las respectivas áreas. Además, el máster nació con una clara vocación de ayuda al Desarrollo. Por ello, se trata de un máster impartido de forma virtual con el propósito de que cualquier alumno, desde cualquier punto lo pueda cursar (a excepción de las prácticas, que son presenciales y que las puede llevar a cabo en diferentes Centros Tecnológicos). En el presente máster se pretende llevar los estudios de tecnología e instrumentación biomédica a titulados superiores de distintas especialidades tanto de la ingeniería como de la biomedicina para la gestión, evaluación y aplicación de la tecnología sanitaria en el ámbito de la salud. Tiene una marcada vocación supranacional, donde la experiencia española y paraguaya en el área de la Ingeniería Biomédica se conjuga para ofrecer a los interesados en dicho postgrado una formación integral, globalizada y sobre todo competitiva. El máster se estructura en tres bloques: uno teórico que se imparte completamente on-line, un Practicum en empresas Tecnológicas y un Trabajo Fin de Máster que se defiende de manera presencial, o bien mediante videoconferencia.Deseamos mostrar nuestro agradecimiento a la Agencia Española de Cooperación Internacional al Desarrollo (AECID) del Ministerio de Asuntos Exteriores, a través de diferentes proyectos (códigos: B/7560/07; D/017286/08; D/025825/09; B/023244/09; A1/040169/11

Máster Virtual en Ingeniería Biomédica con Cooperación al Desarrollo

En el presente trabajo presentamos nuestra experiencia en desarrollar un programa de máster oficial en Ingeniería Biomédica. Para ello nos planteamos un lugar en común con las ingenierías en el cual las necesidades en salud pudieran ser percibidas por los ingenieros a fin de desarrollar soluciones. Para conseguir el nivel adecuado, consideramos fundamental que la docencia de los conocimientos sea realizada por expertos de las respectivas áreas. Además, el máster nació con una clara vocación de ayuda al Desarrollo. Por ello, se trata de un máster impartido de forma virtual con el propósito de que cualquier alumno, desde cualquier punto lo pueda cursar (a excepción de las prácticas, que son presenciales y que las puede llevar a cabo en diferentes Centros Tecnológicos). En el presente máster se pretende llevar los estudios de tecnología e instrumentación biomédica a titulados superiores de distintas especialidades tanto de la ingeniería como de la biomedicina para la gestión, evaluación y aplicación de la tecnología sanitaria en el ámbito de la salud. Tiene una marcada vocación supranacional, donde la experiencia española y paraguaya en el área de la Ingeniería Biomédica se conjuga para ofrecer a los interesados en dicho postgrado una formación integral, globalizada y sobre todo competitiva. El máster se estructura en tres bloques: uno teórico que se imparte completamente on-line, un Practicum en empresas Tecnológicas y un Trabajo Fin de Máster que se defiende de manera presencial, o bien mediante videoconferencia.Deseamos mostrar nuestro agradecimiento a la Agencia Española de Cooperación Internacional al Desarrollo (AECID) del Ministerio de Asuntos Exteriores, a través de diferentes proyectos (códigos: B/7560/07; D/017286/08; D/025825/09; B/023244/09; A1/040169/11

Pretreatment with Resveratrol Prevents Neuronal Injury and Cognitive Deficits Induced by Perinatal Hypoxia-Ischemia in Rats

Despite advances in neonatal care, hypoxic-ischemic brain injury is still a serious clinical problem, which is responsible for many cases of perinatal mortality, cerebral palsy, motor impairment and cognitive deficits. Resveratrol, a natural polyphenol with important anti-oxidant and anti-inflammatory properties, is present in grapevines, peanuts and pomegranates. The aim of the present work was to evaluate the possible neuroprotective effect of resveratrol when administered before or immediately after a hypoxic-ischemic brain event in neonatal rats by analyzing brain damage, the mitochondrial status and long-term cognitive impairment. Our results indicate that pretreatment with resveratrol protects against brain damage, reducing infarct volume, preserving myelination and minimizing the astroglial reactive response. Moreover its neuroprotective effect was found to be long lasting, as behavioral outcomes were significantly improved at adulthood. We speculate that one of the mechanisms for this neuroprotection may be related to the maintenance of the mitochondrial inner membrane integrity and potential, and to the reduction of reactive oxygen species. Curiously, none of these protective features was observed when resveratrol was administered immediately after hypoxia-ischemia.Funding was provided by Basque Government IT 773/13 and BFI-2011-129. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Role of Antioxidants in Neonatal Hypoxic–Ischemic Brain Injury: New Therapeutic Approaches

Hypoxic-ischemic brain damage is an alarming health and economic problem in spite of the advances in neonatal care. It can cause mortality or detrimental neurological disorders such as cerebral palsy, motor impairment and cognitive deficits in neonates. When hypoxia-ischemia occurs, a multi-faceted cascade of events starts out, which can eventually cause cell death. Lower levels of oxygen due to reduced blood supply increase the production of reactive oxygen species, which leads to oxidative stress, a higher concentration of free cytosolic calcium and impaired mitochondrial function, triggering the activation of apoptotic pathways, DNA fragmentation and cell death. The high incidence of this type of lesion in newborns can be partly attributed to the fact that the developing brain is particularly vulnerable to oxidative stress. Since antioxidants can safely interact with free radicals and terminate that chain reaction before vital molecules are damaged, exogenous antioxidant therapy may have the potential to diminish cellular damage caused by hypoxia-ischemia. In this review, we focus on the neuroprotective effects of antioxidant treatments against perinatal hypoxic-ischemic brain injury, in the light of the most recent advances

Effects of Cannabidiol, Hypothermia, and Their Combination in Newborn Rats with Hypoxic-Ischemic Encephalopathy

Therapeutic hypothermia is well established as a standard treatment for infants with hypoxic-ischemic (HI) encephalopathy but it is only partially effective. The potential for combination treatments to augment hypothermic neuroprotection has major relevance. Our aim was to assess the effects of treating newborn rats following HI injury with cannabidiol (CBD) at 0.1 or 1 mg/kg, i.p., in normothermic (37.5°C) and hypothermic (32.0°C) conditions, from 7 d of age (neonatal phase) to 37 d of age (juvenile phase). Placebo or CBD was administered at 0.5, 24, and 48 h after HI injury. Two sensorimotor (rotarod and cylinder rearing) and two cognitive (novel object recognition and T-maze) tests were conducted 30 d after HI. The extent of brain damage was determined by magnetic resonance imaging, histologic evaluation, magnetic resonance spectroscopy, amplitude-integrated electroencephalography, and Western blotting. At 37 d, the HI insult produced impairments in all neurobehavioral scores (cognitive and sensorimotor tests), brain activity (electroencephalography), neuropathological score (temporoparietal cortexes and CA1 layer of hippocampus), lesion volume, magnetic resonance biomarkers of brain injury (metabolic dysfunction, excitotoxicity, neural damage, and mitochondrial impairment), oxidative stress, and inflammation (TNFα). We observed that CBD or hypothermia (to a lesser extent than CBD) alone improved cognitive and motor functions, as well as brain activity. When used together, CBD and hypothermia ameliorated brain excitotoxicity, oxidative stress, and inflammation, reduced brain infarct volume, lessened the extent of histologic damage, and demonstrated additivity in some parameters. Thus, coadministration of CBD and hypothermia could complement each other in their specific mechanisms to provide neuroprotection.F.J.A. has a research agreement with GW Research Ltd, which is now a part of Jazz Pharmaceuticals, from which he receives financial support. W.H. is an employee Jazz Pharmaceuticals. The authors declare no other competing financial interests. The present study was supported by Grant GWCRI1547 (GW Research Ltd., now part of Jazz Pharmaceuticals); Grant PI12/0852 (ISCIII-General SubDirectorate for Research Assessment and Promotion and the European Regional Development Funds/European Social Fund: “A way to build Europe”); and Grant UPV GIU 17/18 (University of the Basque Country)

The Long-Term Neuroprotective Effect of the Endocannabinoid 2-AG and Modulation of the SGZ’s Neurogenic Response after Neonatal Hypoxia-Ischemia

Neonatal hypoxia-ischemia (HI) often causes hypoxic-ischemic encephalopathy (HIE), a neurological condition that can lead to overall disability in newborns. The only treatment available for affected neonates is therapeutic hypothermia; however, cooling is not always effective to prevent the deleterious effects of HI, so compounds such as cannabinoids are currently under research as new therapies. Modulating the endocannabinoid system (ECS) may reduce brain damage and/or stimulate cell proliferation at the neurogenic niches. Further, the long-term effects of cannabinoid treatment are not so clear. Here, we studied the middle- and long-term effects of 2-AG, the most abundant endocannabinoid in the perinatal period after HI in neonatal rats. At middle-term (postnatal day 14), 2-AG reduced brain injury and increased SGZ’s cell proliferation and the number of neuroblasts. At post-natal day 90, the treatment with the endocannabinoid showed global and local protection, suggesting long-lasting neuroprotective effects of 2-AG after neonatal HI in rats.This research was funded by EITB Maratoia-BIOEF, grant BIO18/IC/003, by MCIN/AEI/10.13039/501100011033, grant MINECOR20/P66 and by the “Programa Investigo” by the European Union-Next Generation EU, grant PIFINVE22/15

RPAS (Remotely Piloted Aircraft Systems) para la elaboración de salidas de campo virtuales como recursos docentes “flipped classroom” para Grados relacionados con Ciencias de la Tierra

El principal objetivo del Proyecto es continuar con el desarrollo de material docente geológico y de recorridos de interés geológico virtuales además del uso de RPAS (Remotely Piloted Aircraft System) aeronaves no tripuladas que permiten acercarse a zonas de difícil accesibilidad. Este proyecto pretende desarrollar prácticas de campo virtuales mediante el manejo de nuevas tecnologías, tanto usando métodos de adquisición y elaboración de datos geológicos (RPAS: Remotely Piloted Aircraft System) como para su presentación y uso de la información y comunicación (TICs)

Clínica jurídica de acción social

Memoria ID-0032. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2017-2018

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Çédille, revista de estudios franceses

Presentació